Lenvatinib in combination with pembrolizumab is in clinical development for the treatment of advanced endometrial cancer. Endometrial cancer is the most common form of womb cancer and originates from the lining of the womb (endometrium). The most common symptoms of this cancer are post-menopausal or irregular vaginal bleeding. For patients with advanced endometrial cancers who progress on platinumbased chemotherapy, there are few treatment options available.
Lenvatinib is a drug that targets several different growth factor receptors including vascular endothelial growth factor (VEGFR) and fibroblast growth factor receptors (FGFR). By blocking these receptors, lenvatinib can reduce tumour growth. Pembrolizumab is a drug that binds to the programmed cell death-1 (PD-1) receptor improve the activity of the immune system to kill cancer cells. If licenced, lenvatinib in combination with pembrolizumab will provide a second line treatment for adults with advanced endometrial cancer who have few therapies available.